MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4143/crt.2025.365

Медицинская библиотека · Cancer research and treatment · 2025

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.

Park Se Hoon, Chang Yen-Hwa, Lee Jae Lyun, Choueiri Toni K, Kimura Go, Chung Jinsoo, Masumori Naoya, Nishimura Kazuo, Kato Minoru, Kato Haruaki, Numakura Kazuyuki, Chang Chao-Hsiang, Anai Satoshi, Tsunemori Hiroyuki, Chen Chung-Hsin, Lin Jianxin, Elfiky Aymen, Burgents Joseph E, Kitamura Hiroshi

СтатьяКлиническое исследование III фазыРандомизированное исследованиеМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: Adjuvant pembrolizumab improved disease-free survival (DFS) and overall survival (OS) versus placebo in participants with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy in the global phase 3 KEYNOTE-564 study. This post hoc subgroup analysis evaluated the efficacy and safety of adjuvant pembrolizumab in East Asian (Japan, South Korea, and Taiwan) participants enrolled in KEYNOTE-564.

MATERIALS AND

METHODS

Eligible participants were randomly assigned 1:1 to receive adjuvant pembrolizumab 200 mg or placebo intravenously every 3 weeks for ≤ 17 cycles. The primary endpoint was DFS by investigator assessment. OS was a key secondary endpoint. Safety was a secondary endpoint.

RESULTS

The East Asian subgroup included 126 participants (pembrolizumab, n=58; placebo, n=68). Median follow-up was 62.1 months (range, 49.6 to 73.0 months). Hazard ratio for DFS with pembrolizumab versus placebo was 0.70 (95% confidence interval 0.41 to 1.20). Median DFS was not reached with pembrolizumab versus 58.8 months with placebo; estimated 48-month rate was 61.3% versus 51.2%. Hazard ratio for OS was 0.47 (95% confidence interval, 0.15 to 1.49). Median OS was not reached with pembrolizumab and placebo; estimated 48-month rate was 94.8% versus 91.2%. Treatment-related adverse events occurred in 70.7% of participants (29.3% grade 3 or 4) receiving pembrolizumab and 36.8% of participants (0.0% grade 3 or 4) receiving placebo. No pembrolizumab-related deaths occurred.

CONCLUSION

In the KEYNOTE-564 East Asian subgroup, adjuvant pembrolizumab provided DFS and OS benefits versus placebo and had a safety profile consistent with the global results. These results further support pembrolizumab as adjuvant treatment for East Asian patients with RCC at increased risk of recurrence after nephrectomy.

Для цитирования: Park Se Hoon, Chang Yen-Hwa, Lee Jae Lyun, Choueiri Toni K, Kimura Go, Chung Jinsoo, Masumori Naoya, Nishimura Kazuo, Kato Minoru, Kato Haruaki, Numakura Kazuyuki, Chang Chao-Hsiang, Anai Satoshi, Tsunemori Hiroyuki, Chen Chung-Hsin, Lin Jianxin, Elfiky Aymen, Burgents Joseph E, Kitamura Hiroshi. Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.. Cancer research and treatment. 2025. DOI: 10.4143/crt.2025.365.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.